15,941 Shares in Bristol Myers Squibb Company $BMY Purchased by Birmingham Capital Management Co. Inc. AL

Birmingham Capital Management Co. Inc. AL acquired a new stake in shares of Bristol Myers Squibb Company (NYSE:BMY) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 15,941 shares of the biopharmaceutical company’s stock, valued at approximately $919,000.

A number of other large investors also recently bought and sold shares of BMY. Davis Asset Management L.P. bought a new position in shares of Bristol Myers Squibb in the 2nd quarter worth about $27,000. Swiss RE Ltd. acquired a new stake in Bristol Myers Squibb during the fourth quarter worth about $25,000. Darwin Wealth Management LLC acquired a new stake in Bristol Myers Squibb during the second quarter worth about $25,000. Addison Advisors LLC bought a new position in Bristol Myers Squibb in the second quarter worth about $32,000. Finally, Bayban acquired a new position in Bristol Myers Squibb in the fourth quarter valued at approximately $31,000. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Performance

Shares of BMY stock opened at $67.68 on Thursday. Bristol Myers Squibb Company has a 12-month low of $42.52 and a 12-month high of $68.64. The company has a debt-to-equity ratio of 1.89, a current ratio of 1.53 and a quick ratio of 1.38. The firm has a market capitalization of $138.25 billion, a price-to-earnings ratio of 14.91, a price-to-earnings-growth ratio of 0.18 and a beta of 0.22. The business has a 50 day simple moving average of $61.25 and a 200 day simple moving average of $59.60.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a return on equity of 66.90% and a net margin of 18.87%.The company had revenue of $12.97 billion during the quarter, compared to analyst estimates of $11.74 billion. During the same quarter in the previous year, the firm posted $1.46 EPS. The firm’s quarterly revenue was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, equities research analysts anticipate that Bristol Myers Squibb Company will post 6.95 EPS for the current year.

Bristol Myers Squibb Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Investors of record on Thursday, July 2nd were given a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a yield of 3.7%. The ex-dividend date was Thursday, July 2nd. Bristol Myers Squibb’s dividend payout ratio is currently 55.51%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on BMY. Raymond James Financial began coverage on Bristol Myers Squibb in a research report on Wednesday, August 5th. They set a “strong-buy” rating on the stock. Piper Sandler initiated coverage on Bristol Myers Squibb in a research note on Wednesday, August 5th. They set an “overweight” rating for the company. Wells Fargo & Company set a $65.00 target price on Bristol Myers Squibb and gave the stock an “equal weight” rating in a research report on Friday, July 31st. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a report on Saturday, June 27th. Finally, Guggenheim restated a “buy” rating and set a $75.00 price target (up from $72.00) on shares of Bristol Myers Squibb in a research report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating, ten have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Bristol Myers Squibb currently has an average rating of “Moderate Buy” and an average target price of $66.06.

Insider Transactions at Bristol Myers Squibb

In other Bristol Myers Squibb news, SVP Phil M. Holzer sold 500 shares of the firm’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the transaction, the senior vice president owned 16,862 shares of the company’s stock, valued at approximately $1,138,185. This trade represents a 2.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 0.05% of the stock is owned by corporate insiders.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.